CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

Stock Information for Alterity Therapeutics Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Alterity Therapeutics Limited

CytomX Therapeutics to Present at Upcoming December Investor Conferences
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
CytomX Therapeutics to Present at Upcoming September Investor Conferences
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.